Twinstrand Therapeutics Files IND Application For Immunogen in Ricin Antidote Study
BURNABY, BC, Canada, September 25, 2007 – Twinstrand Therapeutics Inc. today announced that it has filed an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration (FDA) for the immunization of humans with a benign ricin-like toxoid.